Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells

The effect of docosahexaenoic acid (DHA) on the killing efficacy of imatinib on HL-60 cells expressing the Bcr-Abl protein was investigated. Imatinib is an Abl tyrosine kinase inhibitor used in the treatment of patients with chronic myeloid leukemia. The pre-treatment with DHA for 24 h raised the ef...

Full description

Saved in:
Bibliographic Details
Published in:Toxicology in vitro 2007-12, Vol.21 (8), p.1678-1685
Main Authors: de Lima, Thais Martins, Amarante-Mendes, Gustavo P., Curi, Rui
Format: Article
Language:English
Subjects:
Antineoplastic Agents - toxicity
Bcr-Abl
Benzamides
Chronic myeloid leukemia
Docosahexaenoic acid
Docosahexaenoic Acids - pharmacology
Dose-Response Relationship, Drug
Drug Synergism
Gene Expression Regulation
Genes, abl - genetics
HL-60 Cells
Humans
Imatinib
Imatinib Mesylate
Piperazines - agonists
Piperazines - toxicity
Pyrimidines - agonists
Pyrimidines - toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of docosahexaenoic acid (DHA) on the killing efficacy of imatinib on HL-60 cells expressing the Bcr-Abl protein was investigated. Imatinib is an Abl tyrosine kinase inhibitor used in the treatment of patients with chronic myeloid leukemia. The pre-treatment with DHA for 24 h raised the effect of imatinib at 100 μM concentration only. On the other hand, after 72 h pre-treatment, all concentrations of DHA tested (25, 50 and 100 μM) enhanced the toxic effect of imatinib. These results indicate that long-term pre-treatment with DHA makes Bcr-Abl HL-60 cells more susceptible to the toxic effect of imatinib.
ISSN:0887-2333
1879-3177
DOI:10.1016/j.tiv.2007.05.008